
Sign up to save your podcasts
Or


Do you ever wonder why it takes so long for new drugs to hit the market? Have you ever questioned the efficiency of the pharmaceutical industry?
Join me in this episode as we talk to Jack Scannell, a pharmaceutical industry expert, and discover the hidden efficiency secrets of drug development. In this episode, we delve into the critical factors that have shaped drug development over the last 60 years and analyze the industry's current state.
Throughout the podcast, Jack draws on his extensive industry knowledge and provides insights on the importance of decision quality, the role of AI in drug discovery, and the economics of the research model.
If you're looking to gain a better understanding of the pharmaceutical industry and its inner workings, join us in uncovering the efficiency secrets of drug development. Tune in to this episode.
💡 LINKS TO MORE CONTENT
If you like the episode, become a subscriber and support the show: https://lsg2g.substack.com/subscribe
Watch on Youtube
Jack Scannell
Christian Soschner
📖 Memorable quotes:
(11:41) “Between 1950 and 2010, Drug Development saw a halving time: Every nine years, the number of drugs developed per billion dollars spent halved.”
(24:58) “4 Reasons for the Decline of Drug Development Productivity: Better Than the Beatles Problem, Higher Regulatory Hurdles, Throw Money at it Problem, Misindustrialisation of Science
(26:30) “Metformin is the Pharmaceutical Equivalent to the Beatles”
(45:15) “In early drug discovery, predictive validity, the degree to which your model output correlates with human clinical utility is critically important”
(01:19:31) “If the only tool you have to measure the height of the fruit is the rate at which you are picking fruit, and you notice that the rate of picking fruit is declining, you will always blame the low hanging fruit problem.”
(01:34:15) “When capital is freely available, the average quality is going down”
⏰ Timestamps:
(00:00) Introduction: Uncovering Drug Development Efficiency Secrets
(06:30) Background Jack Scannell: Pharma Journey
(09:15) Finding erooM’s Law: Playful Experiment Leads to Discovery
(12:00) Inversion of Output Efficiency: More Capital, Fewer Drugs
(13:15) Best Key Figure for R&D Productivity?
(20:24) Factors Behind R&D Productivity Decline - 1950 to 2010
(25:30) The Beatles Inform Drug Development
(28:34) The Regulatory Problem
(30:00) Throwing Money at the Problem & Misindustrialisation of Science
(31:00) Turnaround in Drug Development Efficiency from 2010
(38:30) Speeding Up Early-Stage R&D
(45:45) Technical & Managerial Components to Improve Speed
(47:10) Improving Predictive Quality of Models - Alzheimer's Case Study
(57:00) Interplay of Different Forces in Complex Problem Solving
(01:02:30) Model Quality Matters the Most for High R&D Quality
(01:12:45) Making Pharma Value Chain More Effective
(01:18:00) Appropriate Success Measure for Drug R&D?
(01:21:05) Role of AI in Drug Discovery Process
(01:29:32) Limiting Factor of AI in Biology?
(01:31:00) Availability of Capital a Limiting Factor in Drug Development?
(01:39:00) Economics of Research Model - Common Goods Problem
(01:47:00) Role of Public Funds to Validate R&D Model Quality
(01:52:00) Truth Seeking Over Progression Seeking Behaviour: Prioritizing Scientific Integrity in Drug Development.
Send us Fan Mail
Support the show
Join the Podcast Newsletter: Link
Your Next Move: Link
Uncover the Secrets of Success with Arnold Schwarzenegger - Mastering the 6 Rules.
In this episode, join us as we delve into the mind of one of the greatest action heroes and successful entrepreneurs of our time.
Arnold Schwarzenegger shares his personal experiences and lessons learned as he reveals the key elements of his famous "6 Rules for Success" speech. Get inspired and motivated as you discover the blueprint for achieving your goals and realizing your dreams.
💡 LINKS TO MORE CONTENT
If you like the episode, become a subscriber and support the show: https://lsg2g.substack.com/subscribe
Podcast Episodes: https://pod.link/1493847125
Check out our partners: https://linktr.ee/lsg2
Watch on Youtube
Christian Soschner
⏰ Timestamps:
(01:34) Rule #1: Have a Vision
(13:12) Rule #2: Ignore the Naysayers
(22:18) Rule #3: Work your A** Off
(28:01) Rule #4: Don’t have a Plan B
(33:38) Rule #5: Give Back
(39:52) Rule #6: You Need Help
Send us Fan Mail
Support the show
Join the Podcast Newsletter: Link
Your Next Move: Link
Are you curious about what it takes to be a female venture capitalist in 2023?
Join us as we sit down with Jeevan, a successful woman in the industry, to discuss the world of female entrepreneurship and venture capitalism. With her insights on the tech focus areas of 2023, the challenges of attracting women into the VC world, and the importance of warm referrals, Jeevan offers a unique perspective on the startup investment landscape. Get a glimpse into the life of a female VC as she shares her journey and valuable lessons learned. Tune in now to learn what it takes to become a venture capitalist in 2023 and expand your knowledge on the exciting world of startup investments.
💡 LINKS TO MORE CONTENT
If you like the episode, become a subscriber and support the show: https://lsg2g.substack.com/subscribe
Podcast Episodes: https://pod.link/1493847125
Check out our partners: https://linktr.ee/lsg2
Watch on Youtube
Jeevan Sunner
Christian Soschner
📖 Memorable quotes:
(49:33) “Linkedin Made Investors in Silicon Valley Accessible”
(49:55) “Communication, Accessibility, Relationship building, and Information sharing make social media super powerful.”
(55:40) “Take your time and do your due diligence on investors to understand whether their values are aligned with yours and whether you see that 10-15 years partnership happening.”
(59:30) “We are flexible in the way we collaborate with founders. It can be a more passive approach, or for first-time founders more hands-on”
(01:09:00) “When it comes to dilution, we rather have a smaller slice of a bigger pie, than a massive slice of a smaller pie”
⏰ Timestamps:
(00:00) Unlocking the Secrets of Venture Capital: An Insider's View
(03:15) Brave the Winter of England with Jeevan in December 2022
(05:44) The Journey to Becoming a Top Venture Capitalist in 2023
(11:00) Spotting the Next Big Tech Trend in 2023
(14:20) Empowering Female Entrepreneurs and VCs to Create Change
(20:00) Breaking Barriers: What it Takes to Attract More Women in Tech VC
(23:00) The Power of Warm Referrals and How VCs Evaluate a Pitch deck
(26:00) Timing is Everything: When is the Right Moment to Approach a VC?
(30:30) A Day in the Life of a Busy Venture Capitalist
(39:30) Decoding Job Titles in Venture Funds: What They Really Mean
(44:15) The Human Side of Investing: Why Relationships are Key
(46:15) 2 Vital Lessons for Founders from a VC's Perspective
(48:55) The Rise of Social Media in the Startup Investment World 2023
(50:35) Podpower: The Importance of Podcasts in Building Relationships in 2023
(52:25) Jeevan's Must-Listen Podcast List for Entrepreneurs and Investors
(56:50) Expectations Beyond Returns: What VCs Look for in Founders
(01:04:30) The Investors' Role in Board Functions and Aligning Interests
(01:09:50) Finding the Perfect Match: Product/Market Fit
(01:13:50) Jeevan's Most Exciting Deal: Behind the Scenes
(01:16:25) The Art of Closing a Deal: A VC's Perspective
(01:17:55) The Challenges of Closing a Deal and the Path to Success
(01:20:45) Predicting the Future of VCs: 2023 and Beyond
(01:25:00) The Final Word: Jeevan's Advice for Entrepreneurs and Investors
Send us Fan Mail
Support the show
Join the Podcast Newsletter: Link
Your Next Move: Link
Are you ready for the grand finale of our Year in Review Recording?
The final episode of 2022 is here, and it's one for the books! We've explored the cutting-edge innovations and technologies shaping the future of the biotech industry with some of the most brilliant minds in the field. From Kurt Höller of EIT Health, to Albert Missbichler from Fianostics, Caroline Heil from the new meat company, Mauricio Agudelo and Lina Toro from Bialtec, Kimberly Cornfield from the UCL, Collin Ewald from ETH Zurich, and Guido Gualdoni from G.ST Antiviral, we've had some truly enlightening conversations.
But we saved the best for last!
Get ready for an exclusive interview with Dr. Thomas Schubert, CEO of 2bind, a provider of biophysical outsourcing solutions that is revolutionizing the way we study molecular interactions and protein stability. Don't miss out on this one-of-a-kind episode.
Tune in now!
This cutting-edge biotech company is revolutionizing how we study molecular interactions and protein stability. They're doing it with a track record of over 1400 successfully completed tasks in research projects with over 350 customers in the last 11 years.
In this episode, you'll get an inside look at the driving force behind 2bind and the expert knowledge that sets them apart in the biophysics field. From breakthrough moments to industry trends, you'll gain a deeper understanding of the future of biotech and the role that companies like 2bind will play in shaping it.
But that's not all! You'll also hear from Dr. Schubert about the company's partnerships with leading device producers and how they navigate the digital world to stay ahead of the curve. Plus, you'll get insight into the supply chain challenges that 2bind faced in the last years and how they overcame them.
Don't miss out on this opportunity to learn from the best in the business! Tune in to our latest podcast episode and join the conversation on the future of biotech.
Trust us; this episode is a must-listen for anyone in the biotech industry or anyone passionate about innovation and the future of medicine. It's packed with valuable insights and information you won't miss.
💡 LINKS TO MORE CONTENT.
If you like the episode, become a subscriber and support the show: https://lsg2g.substack.com/subscribe
Podcast Episodes: https://pod.link/1493847125
Check out our partners: https://linktr.ee/lsg2
Watch on Youtube
Thomas Schubert
Christian Soschner
⏰ Timestamps:
00:00) Introduction
(02:00) Unveiling the mastermind behind 2bind, Dr. Thomas Schubert
(04:05) Insider tips for starting your own biotech company
(07:36) A glimpse into the future: 2022 for 2bind's CEO
(10:40) Navigating the digital world: Pros and cons of technology in biotech
(14:16) Overcoming obstacles: A look at 2bind's supply chain challenges
(18:21) Game-changing developments in biophysics for 2022
(19:53) What's next for the industry? A preview of biophysics trends to come
(23:19) Peeking into the crystal ball: 2bind's plans for 2023
(24:25) Mark your calendars: Upcoming conferences featuring 2bind in 2023
(30:49) Bold predictions for the biotech industry in 2023
(32:33) Addressing the challenges: How to improve drug discovery and development in 2023.
Send us Fan Mail
Support the show
Join the Podcast Newsletter: Link
Your Next Move: Link
On this episode of "Year in Review Recording," we speak with Guido Gualdoni, Co-Founder, and CEO of G.ST Antivirals, a clinical-stage biotech company revolutionizing how we treat viral infections of the respiratory tract.
Guido shares the science behind G.ST Antivirals' innovative host cell-based strategy to develop broad-spectrum antivirals and how it completely eliminates viral reproduction without the risk of resistance development. He also delves into the public funding and startup ecosystem in Vienna, Austria, which has been instrumental in the company's success.
He also talks about the future plans for G.ST Antivirals and the deep scientific tech valley in Central Europe. This episode is a must-listen for anyone interested in the latest advancements in biotech and the companies leading the way in treating viral infections.
💡 LINKS TO MORE CONTENT.
If you like the episode, become a subscriber and support the show: https://lsg2g.substack.com/subscribe
Podcast Episodes: https://pod.link/1493847125
Please support this show by checking out the companies that make it possible: https://linktr.ee/lsg2
Watch on Youtube
Guido Gualdoni
Christian Soschner
⏰ Timestamps:
(00:00) Welcome to the Episode: Exploring the Public Funding and Eco-System in Vienna, Austria
(02:35) Meet Guido Gualdoni, CEO of G.ST Antiviral
(04:00) Discovering the StartUp Labs, Vienna Business Agency, AWS, FFG, Austrian Business Agency, LISA Vienna and their role in supporting startups
(07:35) Exploring the Scientific Deep Tech Valley in Central Europe: Munich, Vienna, Zurich, Prague
(10:15) G.ST Antiviral's 2022 Outlook
(11:22) Uncovering the Innovative Technology Behind G.ST Antiviral
(14:30) Guido's Biggest Takeaways from 2022
(16:15) Why Optimism Bias Can be a Challenge for Entrepreneurs
(18:15) Comparing the Scientific and Entrepreneurial Mindsets
(24:00) The Surprising Companies that Succeeded During Economic Downturns
(25:00) Examining the Latest Trends in Antiinfectious Diseases
(27:45) Charting the Growth of G.ST Antiviral in 2023
Send us Fan Mail
Support the show
Join the Podcast Newsletter: Link
Your Next Move: Link
Introducing "The Year in Review Recordings", a series where we reflect on the past year and look forward to the coming one. Hosted by Christian Soschner, this podcast brings you expert speakers from previous episodes and partners of the podcast to give you an in-depth analysis of the latest advancements in their fields and an outlook for the future. This is the 6th conversation in the series.
In this episode, we have Dr. Collin Y. Ewald, founder and president of the Swiss Society for Aging Research and head of the Extracellular Matrix Regeneration Laboratory at the Department of Health Sciences and Technology. Dr. Ewald has a longstanding interest in the molecular biology of healthy aging and age-related pathologies. He is a leading expert in the field and has received multiple awards, including NYAS Future Entrepreneur, recognized by the New York Academy of Sciences. He is named among the top 1000 Longevity Leaders worldwide and the top 15 Longevity Influencers in Switzerland.
We'll be discussing Dr. Ewald's recent work on the expression of extracellular matrix genes during aging, the role of the mTOR kinase in aging, and the challenges of bridging gaps in longevity research between scientific disciplines and languages. We'll also be discussing the Ewald Lab's recent work on the expression of extracellular matrix genes during aging, the role of the mTOR kinase in aging, and the challenges of bridging gaps in longevity research between scientific disciplines and languages.
This episode also includes topics such as Longevity Research and Horizon Europe, How to Bridge the Gap in Horizon Programs between scientific disciplines and different languages, The 9 Hallmarks of Ageing, Solving the Clinical Trial Challenges in Longevity Research, Food Supplements for Longevity in 2023, Collin Ewald’s Spin Out Company, The 10 Simple Rules to Start a Successful Spin-Off Company, 2023 in Longevity Research – Upcoming Trends.
Don't miss out on this episode of "The Year in Review Recordings," where we dive into the world of longevity research with Dr. Collin Y. Ewald and stay informed about the latest advancements in the field.
💡 LINKS TO MORE CONTENT.
If you like the episode, become a subscriber and support the show: https://lsg2g.substack.com/subscribe
Podcast Episodes: https://pod.link/1493847125
Please support this show by checking out the companies that make it possible: https://linktr.ee/lsg2
Watch on Youtube
Collin Ewald
Christian Soschner
⏰ Timestamps:
(00:00) Intro
(03:00) Welcome Note Collin Ewald
(04:25) Longevity Highlights in 2022 in the Ewald Lab, ETH Zurich
(07:08) Published Results of a 9 year study to understand the mTOR Kinase and its role in ageing better
(08:52) Longevity Research and Horizon Europe
(11:08) How to Bridge the Gap in Horizon Programs between scientific disciplines and different languages?
(14:35) Highlights in the Longevity Research Area in 2022
(17:08) The 9 Hallmarks of Ageing
(23:17) Solving the Clinical Trial Challenges in Longevity Research
(25:09) Food Supplements for Longevity in 2023
(28:37) Collin Ewald’s Spin Out Company
(30:37) The 10 Simple Rules to Start a Successful Spin Off Company
(35:49) 2023 in Longevity Research – Upcoming Trends
Send us Fan Mail
Support the show
Join the Podcast Newsletter: Link
Your Next Move: Link
Are you ready to unlock the secrets of securing funding and achieving impact in the world of European research and innovation?
In this episode of our podcast, we explore the latest trends and developments in research and innovation with Kimberly Cornfield, Assistant Director (Project Development & Management) and Head of European Research and Innovation at University College London (UCL). UCL is one of the top-performing universities under the EU's Horizon 2020 program and has secured around €400 million over the last seven years to support its research and innovation activities.
Kimberly and her team connect scientists and businesses around EU collaborative funding opportunities and offer a suite of support services to improve the chances of success in obtaining funding and achieving impact objectives.
We'll discuss the current state of European research funding, the challenges and benefits of virtual meetings, and the future for research and innovation.
💡 LINKS TO MORE CONTENT.
If you like the episode, become a subscriber and support the show: https://lsg2g.substack.com/subscribe
Podcast Episodes: https://pod.link/1493847125
Please support this show by checking out the companies that make it possible: https://linktr.ee/lsg2
Watch on Youtube
Kimberly Cornfield
Christian Soschner
⏰ Timestamps:
(00:00) Introduction Kimberly Cornfield, UCL, and Horizon Europe
(05:12) Highlights UCL and Horizon Europe Grant Funding in 2022
(07:20) Advantages and Challenges – Virtual or Real Life Meetings?
(09:00) Benefits of the Virtual World for UCL Research Projects
(10:21) Horizon Europe
(14:28) Future Trends in Research
(17:28) The Rise of Social Sciences
(19:28) The Relevance of Fairy Tales for Research
(23:05) The Horizon Europe Work Programme for 2023
(26:00) Wishes for 2023
Send us Fan Mail
Support the show
Join the Podcast Newsletter: Link
Your Next Move: Link
Are you ready to discover the secrets of precision nutrition and AI in the animal protein industry?
Join us as we speak with the founders of BIALTEC, Mauricio Agudelo and Lina Maria Toro, to gain exclusive insights on the industry's challenges and opportunities.
From tackling logistics and inflation to understanding the future of animal nutrition, this episode is packed with game-changing information you won't want to miss.
Tune in now and get ready to be inspired by the innovation and vision of BIALTEC.
💡 LINKS TO MORE CONTENT.
If you like the episode, become a subscriber and support the show: https://lsg2g.substack.com/subscribe
Podcast Episodes: https://pod.link/1493847125
Please support this show by checking out the companies that make it possible: https://linktr.ee/lsg2
Watch on Youtube
Christian Soschner
Mauricio Agudelo
Lina Toro
⏰ Timestamps:
(00:00) Introduction Lina Toro and Mauricio Agudelo, Founders at Bialtec
(05:54) Creating Microbiomes for Animals
(09:13) Big Challenges in 2022 for Bialtec – Logistics and Inflation
(11:38) How did Lina Toro, CFO of Bialtec, deal with the global environment
(13:31) Perceived Inflation Rate in the Bialtec Eco-System
(14:19) Energy Prices in South America in 2022
(16:40) Bialtec’s Activities in Europe
(20:22) 3 Improvements for Founding a Company in Europe
(25:28) Trends in the Animal Nutrition Industry in 2023
Send us Fan Mail
Support the show
Join the Podcast Newsletter: Link
Your Next Move: Link
Are we on the brink of a technological revolution that will render content creators obsolete?
Join us as we explore the rise of ChatGPT and its potential impact on the creative industry. From its capabilities as a natural language processing tool to its comparison to Bitcoin in the financial world, we'll discuss the pros and cons of this game-changing technology. Tune in to discover the truth behind the hype and what it means for content creators like you.
Youtube Video
⏰ Timestamps:
(00:00) What Novel Technology Means
(03:30) What is ChatGPT?
(04:50) What Does ChatGPT Mean for the Creative Industry - ChatGPT Usecases
(06:45) How ChatGPT can help in the Brainstorming/ideation Phase
(10:00) Utilizing the Research Phase with ChatGPT
(12:15) How can ChatGPT Help with Producing a Piece of Content?
(15:38) ChatGPT as a Team for Rewriting, Editing, and Repurposing Content to Make it Native to Different Platforms
(18:00) Ethical and Legal Questions
🔗 Podcastlinks:
Episodes
Full Youtube Playlist
Full Clips Playlist
Partner Links
Christian Soschner
Send us Fan Mail
Support the show
Join the Podcast Newsletter: Link
Your Next Move: Link
Celebrate with us as we reach our 100th podcast episode!
Join us as we look back on the past three years and revisit the 5 most downloaded episodes.
From exploring the use of blockchain technology in the energy sector, to gaining valuable insights into the daily life of a VC and learning how to succeed in the competitive world of drug development, this special episode has something for everyone.
Thank you for being a part of our journey and for supporting our mission to promote scientific entrepreneurs and shape a bright future for humanity. Don't miss out on this celebratory milestone episode!
💡 LINKS TO MORE CONTENT.
If you like the episode, become a subscriber and support the show: https://lsg2g.substack.com/subscribe
Podcast Episodes: https://pod.link/1493847125
Please support this show by checking out the companies that make it possible: https://linktr.ee/lsg2
⏰ Timestamps:
(00:00) Episode 100
(03:15) #5: Sascha Bucher – Forty51 Ventures
(14:35) #4: Ana Trbovich – Grid Singularity
(28:22) #3: Jonathan Sporn – Gilgamesh Pharmaceutical
(44:35) #2: Heike Schön – Lumis International
(01:04:00) #1: Alexander Belcredi – Biontech Austria
(01:18:00) Outlook for 2023
Send us Fan Mail
Support the show
Join the Podcast Newsletter: Link
Your Next Move: Link